Olink Holding AB

Olink Holding AB provides accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. The firm offers a platform of products and services which are deployed across major biopharmaceutical companies and clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. It operates through the following segments: Kit and Service. The company was founded on December 13, 2018 and is headquartered in Uppsala, Sweden.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Olink Holding AB exceeds revenue goals, eyes proteomics market growth

Olink had a successful Q4 and 2022, exceeding revenue goals and showcasing innovation.
The company is poised for growth in the proteomics market with a focus on data quality.
Challenges include shifting revenue mix, expanding installations, and meeting customer demands.
Opportunities lie in developing new assays, expanding the protein library, and leveraging positive customer feedback.

Olink Holding AB reports robust Q1 growth and eyes profitability

Olink Holding AB's Q1 2023 performance reflects strong revenue growth and a focus on innovation in next-generation proteomics.
Despite challenges in certain regions and operating at a net loss, the company maintains positive cash flow and aims for profitability in 2023.
Opportunities lie in market expansion, M&A activities, and improving kit gross margins through R&D efforts.
Overall, Olink's unique positioning in the life science space and commitment to serving diverse customer needs underpin its growth potential.

Olink Holding AB (OLK) sees strong revenue growth and market optimism

Olink Holding AB (OLK) reports solid revenue growth in Q2 2023, driven by Explore revenue and scientific productivity. Despite challenges in profitability and margin improvements, the company is optimistic about the market impact of Explore HT and back-half growth potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Olink Holding AB is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science.

This is a translation of the Swedish original. In case of any discrepancies between this translation and the  Swedish original, the latter shall prevail.

Notice to attend the Extra General Meeting of Olink Holding AB (publ)

Thermo Fisher Scientific

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has completed its acquisition of Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions. The transaction values Olink at approximately $3.1 billion, net of $96 million of acquired cash. Olink will become part of Thermo Fisher's Life Sciences Solutions segment. “We are excited to welcome Oli.

Thermo Fisher Scientific Completes Acquisition of Olink, Announces Commencement of Subsequent Offering Period

Olink's (OLK) buyout by Thermo Fisher gets CMA's approval, signaling regulatory confidence in the merger's compliance with competition laws.

Olink's (OLK) Acquisition by Thermo Fisher Gets UK CMA Nod

UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the UK Competition and Markets Authority (the “CMA”) has unconditionally approved the previously announced tender offer (the “Offer”) by Orion Acquisition AB (the “Buyer”), a wholly owned subsidiary of Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher” or “Parent”), for all outstanding Common Shares and American Depositary Shares (together, the “Shares”) of Olink for $26.00 per Share.

Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher

UK's competition regulator said on Monday it has cleared U.S. medical equipment maker Thermo Fisher Scientific's $3.1 billion deal to buy Swedish biotech firm Olink Holding AB.

UK's competition regulator clears $3.1 bln Thermo Fisher Scientific-Olink deal

UPPSALA, Sweden, July 05, 2024 (GLOBE NEWSWIRE) -- At the Extra General Meeting (the “EGM”) of Olink Holding AB (publ), reg. no 559189-7755, (the “Company”), the EGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the EGM and the complete proposals, which have previously been published and are available on the Company's website, www.olink.com.

Report from the Extra General Meeting of Olink Holding AB (publ) on 5 July 2024

UPPSALA, Sweden, July 03, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK), a global leader in proteomics, introduces its inaugural network of Olink® Certified Service Providers. The group of Olink Certified Service Providers represent leading contract research organizations (CROs) and service labs around the world.

Olink® Introduces Global Network of Certified Service Providers to Accelerate Protein Biomarker Discovery

UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research.

Olink® Target 48 Immune Surveillance Panel – The Next Frontier in Immune Biomarker Profiling with Absolute Confidence

Akoya Biosciences Inc

Bionano Genomics

Cytek Biosciences

Danaher

Standard BioTools Inc

908 Devices

Singular Genomics Systems

QIAGEN

Quantum-Si

Revvity Inc

Seer

10X Genomics

Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.

Lab Instrument Industry Update - New Commercial Entrants

Olink Holding AB (publ) Sponsored ADR (OLK) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.11 per share a year ago.

Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q1 Loss, Lags Revenue Estimates

UPPSALA, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the first quarter ended March 31, 2024.

Olink reports first quarter 2024 financial results

Britain's competition regulator said on Friday it has initiated a probe into U.S. medical equipment maker Thermo Fisher Scientific's $3.1 billion deal to buy Swedish biotech firm Olink Holding AB.

UK's CMA kicks off probe into Thermo Fisher-Olink deal

PISCATAWAY, N.J.--(BUSINESS WIRE)-- #Genomics--Sampled1 today announced that it has been named one of the first Olink® Certified Service Providers Olink's state-of-the-art proteomics technology enables understanding of complex biological pathways and disease markers. Proteomics technology is an important tool for studying diseases, providing crucial insights into their underlying molecular mechanisms. The consistent and highly accurate results produced by Olink's Proximity Extension Assay (PEA) technology.

Sampled Named One of the First Olink® Certified Service Providers

UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the “AGM”) of Olink Holding AB (publ), reg. no 559189-7755, (the “Company”), on 19 April 2024 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company's website, www.olink.com.

Report from the Annual General Meeting of Olink Holding AB (publ) on 19 April 2024

UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023.

Olink reports fourth quarter and full year 2023 financial results

UPPSALA, Sweden, March 15, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the “Company” or “Olink”), reg. no. 559189-7755, are hereby given notice to attend the Annual General Meeting to be held at 4:00 p.m. CET on Friday the 19 April 2024, in the Company's facilities at Salagatan 16A, Uppsala. Registration for the meeting commences at 3:30 p.m. CET.

Notice to attend the Annual General Meeting of Olink Holding AB (publ)

UPPSALA, Sweden, March 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Olink's 2024 Annual General Meeting (“AGM”) will be held in Uppsala, Sweden on April 19th, 2024. The AGM was previously scheduled to take place on April 17th, 2024.

Olink announces change of date for Annual General Meeting

Quantum-Si has a ton of promise if the proteomics market continues to develop. Thermo Fisher indicated the future potential with its big pending acquisition of Olink.

Forget Quantum-Si Stock, Olink Acquirer Thermo Fisher Is a Better Long-Term Investment

UPPSALA, Sweden, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the third quarter ended September 30, 2023.

Olink reports third quarter 2023 financial results

Olink (OLK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Olink (OLK)

Novogene AMEA to begin offering Olink Explore HT high-throughput proteomics services to unravel the connections between genes, proteins, and diseases.

Novogene Asia Pacific Middle East and Africa adopts Olink® Explore HT technology to accelerate multi-omics research with next generation proteomics

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Olink Holding AB (publ) (NasdaqGS: OLK) to Thermo Fisher Scientific Inc. (NYSE: TMO). Under the terms of the proposed transaction, shareholders of Olink will receive $26.00 in cash for each common share of Olink that they own. KSF is seeking to determine whether this consideration and the process that led to i.

OLINK HOLDING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Olink Holding AB - OLK

Structure Therapeutics Inc

ImmunityBio

Structure Therapeutics' weight-loss drug candidate is attracting attention over excitement about obesity treatments. ImmunityBio rallied on hopes that its bladder cancer drug will now be better understood by the FDA.

Should You Still Buy the Nasdaq's Best-Performing October Stocks?

Olink Holding AB (publ) Sponsored ADR (OLK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Olink Holding AB (publ) Sponsored ADR (OLK) to Report a Decline in Earnings: What to Look Out for

WALTHAM, Mass. & UPPSALA, Sweden--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, and Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions, today announced that Thermo Fisher has commenced the previously announced tender offer (the “Offer") through a direct, wholly owned subsidiary of Thermo Fisher (the “Buyer”) to acquire all of the outstanding common shares and all of the.

News for Olink Holding AB Stock (OLK)